32 results about "Vancomycin-resistant Enterococcus" patented technology

The invention belongs to the technical field of medicines and in particular relates to application of an indol-ethylene substituted quinoline derivative in preparing drug-resistance bacterium medicines. The invention provides application of the indol-ethylene substituted quinoline derivative of formula (I) as shown in the specification in preparing drug-resistance bacterium medicines. The indol-ethylene substituted quinoline derivative provided by the invention has a remarkable inhibition function upon multiple drug-resistance bacteria, and is capable of remarkably inhibiting growth and propagation of vancomycin-resistant enterococcus, drug-resistant escherichia coli and methicillin-resistant staphylococcus aureus. Deep structure and function study shows that the indol-ethylene substitutedquinoline derivative provided by the invention has an action target of a bacterium split protein FtsZ, because of differences of FtsZ and human micro-tube protein sequences, drug-resistance bacteriummedicines which can selectively act upon bacteria FtsZ without interfering host cells can be designed, and the derivative is good in antibacterial activity, is capable of reducing amounts of single medicines, then reducing toxic and side effects and reducing drug resistance, and has the prospect of being developed into novel antibiotic medicines.

The invention specifically relates to gorgonian-originated fungus secondary metabolite derivatives and application of the same as antiseptics, belonging to the field of medicine. The derivatives provided by the invention exert strong inhibitory effect on methicillin-resistant staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE) and certain inhibitory effect on Gram-negative bacteria; and the minimal inhibition concentrations MIC of the derivatives are all less than 12.5 mu M, which proves that the derivatives can be developed into potential antibacterial drugs.

The invention relates to a vancomycin-resistant enterococcus multiplex fluorescence quantitative PCR (polymerase chain reaction) detection kit. The kit comprises a VanA specific primer, a VanB specific primer, a VanA fluorescent probe, a VanB fluorescent probe, a PCR buffer solution, a deoxynucleoside triphosphate mixture, a DNA (deoxyribonucleic acid) polymerase, a VanA gene standard product sequence and a VanB gene standard product sequence. The kit disclosed by the invention has the beneficial effects that due to the adoption of the PCR detection method, accurate, fast and quantitative detection can be realized.

The invention belongs to the field of medicinal chemistry, and discloses a dialkyl cationic amphiphilic antibacterial peptide analogue with antibacterial activity and a synthesis method thereof. Through four-step reaction, a target product can be simply and fast obtained. A major structure is shown as the accompanying drawing. In-vitro antibacterial activity experiments prove that the most compounds in the series show good antibacterial effects on staphylococcus aureus and escherichia coli; partial compounds show excellent antibacterial activity on super bacteria including MRSA (methicillin-resistance staphylococcus aureus), VRE (vancomycin-resistant enterococcus) and CRE (carbapenemase enterobacteriaceae). In-vitro red cell toxicity experiments also show the series of compounds have low red cell toxicity, so that the series of compounds are hopeful to be used as novel antibacterial candidate medicine. The formulas are shown in the description.

The invention discloses a pharmaceutical composition and application thereof. The pharmaceutical composition is a compound expressed in the formula (I) or a pharmaceutically acceptable salt and a pharmaceutically acceptable carrier thereof. The formula (I) is as shown in description. The pharmaceutical composition can be used for preparing antibacterial medicines and can be especially used for preparing medicines for preventing or treating diseases infected by vancomycin-resistant bacteria. Experiment data shows that the compound can be used for effectively inhibiting the growth of vancomycin-resistant enterococcus when the compound is combined with glycopeptides antibacterial medicines.

Disclosed are synthesized derivatives of a natural product, (±)-marinopyrrole A, shown as structural formula I, which have inhibition activities on gram-positive bacteria, such as methicillin sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), oxacilline-resistant Staphylococcus aureus (ORSA), methicillin-resistant Staphylococcus epidermidis (MRSE) and the like. Furthermore, the methods for preparing (±)-marinopyrrole A and the derivatives thereof are disclosed. According to the study of antibacterial activity in vitro, the synthesized derivatives of the natural product (±)-marinopyrrole A have excellent antibiotic activities on the gram-positive bacteria, such as methicillin sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), oxacilline-resistant Staphylococcus aureus (ORSA), methicillin-resistant Staphylococcus epidermidis (MRSE) and the like, and have potential prospects in clinical application.

An anti-methicillin-resistant Staphylococcus aureus agent (anti-MRSA agent) and an anti-vancomycin-resistant Enterococcus agent (anti-VRE agent) contain as an active ingredient an Oobagi extract extracted from Oobagi with an extraction solvent including at least an organic solvent. Alternatively, the anti-MRSA agent and the anti-VRE agent contain as an active ingredient at least one selected from nymphaeol-A, nymphaeol-B, and nymphaeol-C.

The present invention provides microbe disinfectants, providing: Drug-resistant microbe disinfectants comprising a chlorous acid aqueous solution for inactivating microbes selected from methicillin-resistant Staphylococcus aureus, multidrug-resistant Pseudomonas aeruginosa, and vancomycin-resistant Enterococcus; and microbe disinfectants, which are made with acidity when applied to gram-negative microbes and with alkalinity when applied to gram-positive microbes. The microbes comprise at least one species of microbes selected from the group consisting of E. coli, Staphylococcus aureus, microbes of genus Bacillus, microbes of genus Paenibacillus, Pseudomonas aeruginosa, Enterococcus, Salmonella enterica, and periodontal disease microbes. The present invention is usable as a microbe disinfectant that is safe to human body and easy to handle as a microbe disinfectant for pretreatment in food processing and produces chlorous acid that generates little chlorine dioxide. The microbe disinfectant comprising a chlorous acid aqueous solution of the present invention can be utilized as a sterilizing agent, food additive, antiseptic, quasi-drug, medicine, etc.

The invention discloses a pharmaceutical composition and application thereof. The pharmaceutical composition contains compounds disclosed as chemical formula (I) or pharmaceutically acceptable salts and a pharmaceutically acceptable carrier. The pharmaceutical composition disclosed by the invention can be used for preparing antibacterial drugs, and especially preparing drugs for preventing or treating vancomycin-resistant bacterial infection diseases. The experimental data indicates that the compounds can effectively inhibit growth of vancomycin-resistant enterococcus when being combined with glycopeptide antibacterial drugs.

Disclosed are an anti-methicillin-resistant Staphylococcus aureus agent (an anti-MRSA agent) and an anti-vancomycin-resistant Enterococcus agent (an anti-VRE agent), each of which comprises, as an active ingredient, an Macaranga tanarius extract that is extracted from a plant Macaranga tanarius with an extraction solvent comprising at least an organic solvent. Alternatively, each of the anti-MRSA agent and the anti-VRE agent may comprise at least one member selected from nymphaeol-A, nymphaeol-B and nymphaeol-C as an active ingredient.

The invention belongs to the technical field of medicinal chemistry, and discloses quatemary ammonium chalcone derivatives resistant to drug-resistance bacteria activities, a preparation method and application of the quatemary ammonium chalcone derivatives. A structural formula is as shown in the description. Proved by invitro antibacterial activity experiments and erythrocyte hemolytic experiments, a large part of compounds in the series of the derivatives have great antibacterial effects and selections on staphylococcus aureus and colonic enterococcus faecalis of gram-positive bacteria, escherichia coli and pseudomonas aeruginosa of gram-negative bacteria. The selected part of compounds show great antimicrobial activities on a plurality of 'superbacteria' including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), carbapenem-resistant enterobacteriaceae (CRE) and new delhi metallo (NDM) carrying NDM genes, and especially show excellent activities on the MRSA. Proved by invitro erythrocyte toxicity experiments, the series of compounds are low in erythrocyte toxicity and can be adopted as new anti-microbial drug candidates.

The invention relates to a vancomycin-resistant enterococcus multiplex fluorescence quantitative PCR (polymerase chain reaction) detection kit. The kit comprises a VanA specific primer, a VanB specific primer, a VanA fluorescent probe, a VanB fluorescent probe, a PCR buffer solution, a deoxynucleoside triphosphate mixture, a DNA (deoxyribonucleic acid) polymerase, a VanA gene standard product sequence and a VanB gene standard product sequence. The kit disclosed by the invention has the beneficial effects that due to the adoption of the PCR detection method, accurate, fast and quantitative detection can be realized.

Methods of use of an anti-methicillin-resistant Staphylococcus aureus agent (anti-MRSA agent) and an anti-vancomycin-resistant Enterococcus agent (anti-VRE agent) contain as an active ingredient a Macaranga tanarius extract extracted from Macaranga tanarius with an extraction solvent including at least an organic solvent are disclosed. The anti-MRSA agent and the anti-VRE agent contain as an active ingredient at least one selected from nymphaeol-A, nymphaeol-B, and nymphaeol-C.

The invention belongs to the technical field of biomedicine, and relates to a gene for mediating drug resistance of vancomycin and application thereof. The drug-resistant gene has a nucleotide sequence of SET ID.1, and protein encoded by the gene has an amino acid sequence of SEQ ID.2. The obtained gene sequence is a novel drug-resistance deciding gene of vancomycin resistant Enterococcus, and can prepare probe sequences of PCR amplification and gene microarray diagnostic probes for clinical diagnosis of resisting infection of the vncomycin resistant Enterococcus. The invention provides a novel detection target of drug-resistant strains for clinical practice, and provides a method for detecting Enterococcus carrying novel vancomycin resistance gene by Real-time PCR and a method for detecting the Enterococcus carrying the novel vancomycin resistance gene by a gene microarray; and the detection methods have the advantages of quickness, accuracy, simple and convenient operation, and the like.

The invention belongs to the field of medicinal chemistry, and discloses a dialkyl cationic amphiphilic antibacterial peptide analogue with antibacterial activity and a synthesis method thereof. Through four-step reaction, a target product can be simply and fast obtained. A major structure is shown as the accompanying drawing. In-vitro antibacterial activity experiments prove that the most compounds in the series show good antibacterial effects on staphylococcus aureus and escherichia coli; partial compounds show excellent antibacterial activity on super bacteria including MRSA (methicillin-resistance staphylococcus aureus), VRE (vancomycin-resistant enterococcus) and CRE (carbapenemase enterobacteriaceae). In-vitro red cell toxicity experiments also show the series of compounds have low red cell toxicity, so that the series of compounds are hopeful to be used as novel antibacterial candidate medicine. The formulas are shown in the description.

The invention relates to application of cinnamaldehyde in preparation of drugs for targeted therapy of bacterial infection, and belongs to the technical field of medicines. Bacteria are multi-drug-resistant bacteria such as methicillin-resistant staphylococcus aureus, carbapenem-resistant baumanii, carbapenem-resistant enterobacteriaceae, carbapenem-resistant pseudomonas aeruginosa or vancomycin-resistant enterococcus. By the research result of the invention, an efficient, low-toxicity and novel antibacterial medicine which is used for targeted therapy of multi-drug-resistant bacterial infection is provided for bacterial infection of departments such as a clinical pneumology department, a hematology department, an emergency treatment ICU, an oncology department and organ grafting, in-vivo pharmacodynamics, an action mechanism and a theoretical experiment basis are provided for research and development of traditional Chinese medicines for treating multi-drug-resistant bacterial infection, and conditions are created for transformation of scientific achievements.